Orbis India Partners Meet 2026 focuses on sustainable, climate-resilient eye care

Green Vision Centres cut emissions, expand community coverage as partners align on resilient eye health systems

C4 Therapeutics and Roche launch bold push into next-generation cancer drug modality

The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation

VDYNE gets FDA nod to launch pivotal US trial for tricuspid valve device

The approval clears the way for a US study at leading clinical centers to evaluate the safety and effectiveness of VDYNE’s system in patients

Aniruddha Rajurkar appointed as CEO of Zenex Animal Health

In his new role, he is expected to further strengthen Zenex Animal Health’s market position and accelerate its next phase of growth.

Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109

The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved

Dharmendra Singh Gangwar appointed CEO of Rajiv Gandhi Cancer Institute

Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation

Merck launches high-stakes trial of dual-action eye drug aiming to halt leading cause of blindness

The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year

Saharsh Davuluri takes over as CEO & MD of Neuland Laboratories

18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist

Emcure Pharma reduces Poviztra starting dose price by 55% in India

The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country

Orca Bio’s Orca-T FDA review extended to July 2026